Table 2.

Summary of the percentage of patients fitting g and d models for the eight radiomics features discovered in the three signatures.

Tumor burdenHeterogeneityBoundaries
Log XLog ZDWT1GLCMGTDMShapeSigmoid
AverageaUniBiVolumeAverageaEntropyEntropyHHLIMC1contrastAverageaSI4Slope
NIVOLUMAB
 Patients analyzed, n (%)Total included129 (81.6)122 (77.2)128 (81.0)137 (86.7)85 (54.1)62 (39.2)88 (55.7)93 (58.9)87 (55.1)97 (61.4)112 (70.6)114 (72.2)109 (69.0)
dx10 (6.6)11 (7)9 (5.7)11 (7)37 (23.4)33 (20.9)34 (21.5)39 (24.7)30 (19)49 (31)29 (18.4)20 (12.7)38 (24.1)
gx77 (48.5)68 (43)75 (47.5)87 (55.1)34 (21.7)39 (24.7)35 (22.2)31 (19.6)30 (19)36 (22.8)63 (39.6)61 (38.6)64 (40.5)
gd37 (23.6)40 (25.3)39 (24.7)33 (20.9)18 (11.7)23 (14.6)15 (9.5)21 (13.3)23 (14.6)10 (6.3)18 (11.1)29 (18.4)6 (3.8)
 Patients not analyzed, n (%)Total excluded29 (18.4)36 (22.8)30 (19.0)21 (13.3)73 (45.9)96 (60.8)70 (44.3)65 (41.1)71 (44.9)61 (38.6)47 (29.4)44 (27.8)49 (31.0)
 Erroneous data1 (0.5)4 (2.5)
 No measurement1 (0.6)1 (0.6)1 (0.6)1 (0.6)1 (0.6)1 (0.6)1 (0.6)1 (0.6)1 (0.6)1 (0.6)4 (2.2)1 (0.6)6 (3.8)
 Two evaluations ≤20% difference17 (10.8)24 (15.2)17 (10.8)10 (6.3)39 (24.8)42 (26.6)42 (26.6)39 (24.7)45 (28.5)28 (17.7)23 (14.6)36 (22.8)10 (6.3)
 Not fit11 (7.0)11 (7)12 (7.6)10 (6.3)25 (15.7)19 (12)23 (14.6)25 (15.8)25 (15.8)32 (20.3)20 (12.7)7 (4.4)33 (20.9)
DOCETAXEL
 Patients analyzed, n (%)Total included49 (74.7)46 (69.7)53 (80.3)49 (74.2)36 (55.2)33 (50.0)33 (50.0)42 (63.6)30 (45.5)44 (66.7)41 (62.1)36 (54.5)46 (69.7)
dx3 (4.0)4 (6.1)2 (3)2 (3)14 (21.2)10 (15.2)13 (19.7)15 (22.7)9 (13.6)23 (34.8)8 (11.4)5 (7.6)10 (15.2)
gx28 (42.9)23 (34.8)32 (48.5)30 (45.5)15 (22.4)15 (22.7)12 (18.2)20 (30.3)14 (21.2)13 (19.7)24 (35.6)15 (22.7)32 (48.5)
gd17 (25.8)18 (27.3)18 (27.3)15 (22.7)7 (11.2)7 (10.6)8 (12.1)7 (10.6)7 (10.6)8 (12.1)9 (12.9)14 (21.2)3 (4.5)
 Patients not analyzed, n (%)Total excluded17 (25.3)20 (30.3)13 (19.7)17 (25.8)30 (44.8)33 (50.0)33 (50.0)24 (36.4)36 (54.5)22 (33.3)25 (37.9)30 (45.5)20 (30.3)
 Erroneous data
 No measurement
 Two evaluations ≤20% difference12 (18.7)19 (28.8)8 (12.1)10 (15.2)20 (30)24 (36.4)23 (34.8)18 (27.3)24 (36.4)10 (15.2)14 (20.5)22 (33.3)5 (7.6)
 Not fit4 (6.6)1 (1.5)5 (7.6)7 (10.6)10 (14.9)9 (13.6)10 (15.2)6 (9.1)12 (18.2)12 (18.2)12 (17.4)8 (12.1)15 (22.7)
GEFITINIB
 Patients analyzed, n (%)Total included5 (10.9)4 (8.7)5 (10.9)6 (13.0)3 (6.5)2 (4.3)3 (6.5)3 (6.5)3 (6.5)4 (8.7)4 (8.7)4 (8.7)4 (8.7)
dx0.7 (1.5)1 (2.2)1 (2.2)0.2 (0.4)1 (2.2)1 (2.2)2 (4.3)
gx0.3 (0.7)1 (2.2)1.8 (3.9)3 (6.5)2 (4.3)2 (4.3)2 (4.3)1 (2.2)1 (2.2)1 (2.2)
gd4 (8.7)3 (6.5)4 (8.7)5 (10.9)1 (2.2)2 (4.3)1 (2.2)2 (4.3)2 (4.3)3 (6.5)1 (2.2)
 Patients not analyzed, n (%)Total excluded41 (89.1)42 (91.3)41 (89.1)40 (87.0)43 (93.5)44 (95.6)43 (93.5)43 (93.5)43 (93.5)42 (91.3)42 (91.3)42 (91.3)42 (91.3)
 Erroneous data
 No measurement0.5 (1.1)1 (2.2)
 Two evaluations ≤20% difference0.7 (1.5)1 (2.2)1 (2.2)1 (2.2)1 (2.2)1 (2.2)1 (2.2)1 (2.2)1 (2.2)
 Not fit0.3 (0.7)1 (2.2)2 (4.3)3 (6.5)2 (4.3)2 (4.3)2 (4.3)1 (2.2)2 (4.3)2 (4.3)2 (4.3)
  • aAverage: average value for the features included in the categories tumor burden, heterogeneity, and boundaries. Uni (Unidimensional), Bi (Bidimensional). Computation of the rate of decay (d) and growth (g) of radiomics features using serial radiographics measurement. The eight features discovered in the three signatures (nivolumab, docetaxel, and gefitinib) are generalized and applied to the three cohorts. In the cohort gefitinib, patients had only two evaluations, hence d and g values were not assessable in most patients.